Lyra Therapeutics Inc (NAS:LYRA)
$ 0.1806 0.0083 (4.82%) Market Cap: 11.28 Mil Enterprise Value: -5.02 Mil PE Ratio: 0 PB Ratio: 0.55 GF Score: 39/100

Q2 2021 Lyra Therapeutics Inc Earnings Call Transcript

Aug 09, 2021 / 08:30PM GMT
Release Date Price: $6.69 (-4.02%)
Operator

Welcome to Lyra Therapeutics' conference call. (Operator Instructions)

Now, I'll turn the call over to Ms. Stephanie Marks with Argot Partners.

Stephanie Marks
Argot Partners - IR

Thank you, operator, and welcome everyone to today's call. With me today are Dr. Maria Palasis, Lyra's President and Chief Executive Officer; Don Elsey, Chief Financial Officer; Dr. Robert Kern, Chief Medical Officer; and Corinne Noyes, SVP of Commercial Strategy and Market Development.

This afternoon, Lyra issued a press release announcing its second-quarter 2021 financial results and business updates. A quarter -- a copy of the announcement can be found in the Investor Relations tab of the company's website, lyratherapeutics.com.

During the conference call, management will make forward-looking statements, including statements related to the clinical development of the company's product candidates, business strategy and planned operations. These forward-looking statements are based on the company's current expectations and inherently involves significant

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot